In humans, the effects of the octapeptide hormone angiotensin II are mediated by two types of receptor, AT 1 R and AT 2 R, which share approximately 34% amino acid sequence identity 1,2 . AT 1 R is mainly responsible for blood pressure regulation, with several antagonists and inverse agonists approved for clinical use as anti-hypertensive drugs 3 . By contrast, the function of AT 2 R is less well understood and remains controversial, with a growing number of studies suggesting that AT 2 R signals primarily via non-canonical, G-protein-and β -arrestinindependent pathways 4,5 . In the cardiovascular system, AT 2 R has been reported to counteract several of the effects mediated by AT 1 R (refs 6, 7), conferring cardioprotection. For example, in the vasculature, AT 2 R has been suggested to counter-balance blood pressure increases exerted by AT 1 R (refs 8, 9). It has also been reported that activation of AT 2 R in cardiomyocytes inhibits autophagy mediated by AT 1 R (ref. 10). Moreover, in the central nervous system, AT 2 R has been implicated in AT 1 R-independent signalling pathways [11][12][13][14] . It has been observed that activation of AT 2 R in nociceptive neurons induces neurite outgrowth and elongation
In humans, the effects of the octapeptide hormone angiotensin II are mediated by two types of receptor, AT 1 R and AT 2 R, which share approximately 34% amino acid sequence identity 1, 2 . AT 1 R is mainly responsible for blood pressure regulation, with several antagonists and inverse agonists approved for clinical use as anti-hypertensive drugs 3 . By contrast, the function of AT 2 R is less well understood and remains controversial, with a growing number of studies suggesting that AT 2 R signals primarily via non-canonical, G-protein-and β -arrestinindependent pathways 4,5 . In the cardiovascular system, AT 2 R has been reported to counteract several of the effects mediated by AT 1 R (refs 6, 7), conferring cardioprotection. For example, in the vasculature, AT 2 R has been suggested to counter-balance blood pressure increases exerted by AT 1 R (refs 8, 9 ). It has also been reported that activation of AT 2 R in cardiomyocytes inhibits autophagy mediated by AT 1 R (ref. 10). Moreover, in the central nervous system, AT 2 R has been implicated in AT 1 R-independent signalling pathways [11] [12] [13] [14] . It has been observed that activation of AT 2 R in nociceptive neurons induces neurite outgrowth and elongation 15 , and studies in sensory neurons selectively expressing AT 2 R but not AT 1 R also support the involvement of AT 2 R in nociception [16] [17] [18] . Further interest in AT 2 R as a drug target has been sparked by the recent finding that the canonical AT 2 R antagonist PD123319 blocks angiotensin-II-induced neuronal excitability, and exhibits oral bioavailability in several neuropathic pain models in rodents [17] [18] [19] . Most excitingly, EMA401, an analogue of PD123319, demonstrated efficacy in phase II clinical trials in patients with post-herpetic neuralgia 16, 20 . Notably, activation of AT 2 R by its small-molecule agonist compound 21 (ref. 21) has also been reported to produce several beneficial in vivo effects, such as inducing pressure natriuresis, lowering blood pressure, conferring acute vasorelaxation, and exhibiting organ-protective effects 22, 23 . We previously reported the crystal structures of AT 1 R in complex with an antagonist ZD7155 (ref. 24) and with an inverse agonist olmesartan 25 , and these provided insights into AT 1 R receptor-ligand interactions. The molecular mechanisms of functional diversity and ligand selectivity between AT 1 R and AT 2 R, however, remain elusive. With an increasing body of evidence indicating that selective targeting of AT 2 R could be used for cardioprotection and for the treatment of neuropathic pain, there is an imminent need to determine the structural basis for the functional role of this receptor, and to develop type-selective ligands. In this study, we determined crystal structures of AT 2 R bound to two high-affinity ligands, an AT 2 R-selective ligand compound 1 (ref. 26 ) and an AT 1 R/AT 2 R dual ligand compound 2 (ref. 27 ). Both compounds are derivatives of a series of small-molecule antagonists of AT 1 R, and thus could be assumed to exert the same function in AT 2 R. However, classification of compounds using traditional G-protein-coupled receptor (GPCR) nomenclature into antagonists or agonists has proven difficult for AT 2 R since it has not been reliably demonstrated to signal through any of the canonical GPCR signalling pathways involving G proteins or β -arrestins. Furthermore, it has been observed numerous times that small changes to the structures of closely related compounds can lead to changes or bias in function 28, 29 . Therefore, we refer to compounds 1 and 2 using the neutral term 'ligand' . In addition to a marked reshaping of the ligand-binding pocket between the two receptors, our AT 2 R structures revealed an active-like conformation of the seven-transmembrane (7TM) helical bundle with a non-canonical positioning of the amphipathic helix VIII, potentially blocking recruitment of intracellular signalling partners.
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Structure determination
The human AT 2 R construct used for structure determination was engineered to facilitate crystallization (Extended Data Fig. 1 ) by truncating the N-terminal residues 1-34 and the C-terminal residues 336-363, and fusing a thermostabilized apocytochrome b 562 RIL (ref. 30) to the truncated N terminus via a four-residue linker. Compared to wildtype AT 2 R, the engineered receptor showed no significant difference in the binding to small-molecule ligands (1 and 2) as determined by radioligand-binding assays (Extended Data Fig. 2a, c, d ). By contrast, the affinities of the peptides angiotensin II and Sar 1 -Ile 8 -angiotensin II were slightly lower (approximately threefold), potentially as a consequence of the N-terminal truncation (Extended Data Fig. 2b) . AT 2 R bound to the selective ligand compound 1 generated a high density of microcrystals in lipidic cubic phase (LCP) 31 with an average size of 5 × 2 × 2 μ m 3 (Extended Data Fig. 3a) . These microcrystals were used to collect serial femtosecond crystallography (SFX) [32] [33] [34] data at an X-ray free-electron laser (XFEL), resulting in two 2.8 Å resolution room temperature structures solved in monoclinic and orthorhombic space groups, respectively (Extended Data Table 1 ). In parallel, we solved another AT 2 R structure in complex with the non-selective AT 1 R/AT 2 R dual ligand compound 2 at 2.9 Å resolution (Extended Data Table 1 ) by synchrotron radiation, using cryo-cooled crystals with an average size of 70 × 40 × 20 μ m 3 (Extended Data Fig. 3b ). All three AT 2 R structures showed nearly identical conformations of the receptor (root mean square deviation (r.m.s.d.) C α value < 0.5 Å). Since the orthorhombic AT 2 R-compound 1 structure is the most complete, we used it for the description of the overall AT 2 R structure below, unless noted otherwise.
Active-like conformation of 7TM bundle
The overall architecture of AT 2 R is comprised of a 7TM bundle (helices I-VII) and an intracellular amphipathic helix VIII (Fig. 1a) . Similar to AT 1 R and other peptide-binding GPCRs 24 , AT 2 R exhibits a β -hairpin conformation of the extracellular loop 2 (ECL2) and two pairs of disulfide bonds linking the N terminus with ECL3 (Cys35 35 ). A closer comparison of the AT 1 R and AT 2 R structures, however, revealed substantially different conformations (Fig. 1b-e) . Although the previously determined AT 1 R structures captured the receptor in a classical inactive state, all three AT 2 R structures, obtained in this work, display an active-like conformation. Specifically, the intracellular end of helix VI shows an outward displacement by approximately 11.5 Å, whereas the intracellular end of helix VII exhibits an inward displacement by 4.9 Å, as compared to the structures of inactive AT 1 R (Fig. 1e) . Similar large-scale shifts of helices VI and VII that open an intracellular cleft for the recruitment of G proteins and β -arrestins have been implicated in the activation of all class A GPCRs 36, 37 . Another major conformational rearrangement occurs at the extracellular end of helix V, which is shifted towards the ligand-binding pocket by around 4.8 Å, compared to AT 1 R (Fig. 1d) . Similar shifts of the extracellular part of helix V, although typically with a smaller 2 Å amplitude, have been observed in structures of several activated GPCRs, such as the β 2 -adrenergic (β 2 AR) and serotonin 5-HT 2B receptors 38, 39 . Such agonist-stabilized displacement of helix V is essential for triggering re-arrangements in the P motif, leading to activation of these receptors [38] [39] [40] . The large-scale re-arrangements of helices during activation are accompanied by conformational changes in the conserved microswitches 36 . We therefore compared the DR 38, 41 . The large-scale movement of helix VI upon activation is enabled by re-arrangements in the P (Fig. 1c) Fig. 4a, b) . Notably, instead of a highly conserved large hydrophobic residue in position 6.37, AT 2 R has a rare alanine residue (~ 3% of class A GPCRs), which markedly reduces the hydrophobic contact area between helices III and VI in the inactive state, and probably facilitates the activation-related changes in AT 2 R. Therefore, all of the major conformational features indicate that the 7TM bundle of AT 2 R adopts an active-like conformation, similar to that observed in the crystal structures of other fully activated class A GPCRs bound to signalling partners or their mimics.
In addition to the conserved microswitches, a sodium-binding site consisting of 16 highly conserved residues is expected to undergo large-scale conformational changes upon activation of class A GPCRs 42 . Superposition of AT 2 R with AT 1 R revealed that the putative sodium-binding pocket in AT 2 R is collapsed and rearranged, hindering sodium ion binding (Extended Data Fig. 4c, d ), mainly owing to the inward shift of helix VII, which is consistent with the structures of other activated GPCRs 42 . Only 2 out of 16 residues in the putative sodium pocket (Ile135 ). Notably, Article reSeArcH mutation of Asn295 7. 46 to Ala was implicated in the AT 1 R constitutive activation 43, 44 , potentially owing to the disruption of two hydrogen bonds between Asn295 7.46 and Asn111 3.35 that stabilize the inactive conformation. By contrast, Ser311 7.46 in AT 2 R cannot engage in a similar interaction with Asn127 3. 35 , potentially shifting the conformational equilibrium towards the active state. Indeed, AT 2 R has been reported to have high constitutive activity, and to induce apoptosis even in the absence of angiotensin II stimulation 45, 46 .
Helix VIII blocks G protein and β -arrestin binding
In most GPCR structures, helix VIII lies parallel to the membrane pointing outside of the 7TM bundle 24 , regardless of the activation state of the receptor (Fig. 2a, b) . Surprisingly, in the AT 2 R structures, helix VIII adopts a very different conformation by flipping over to interact with the intracellular ends of helices III, V and VI (Fig. 2c ). This non-canonical conformation of helix VIII was found in all AT 2 R structures determined in this study, regardless of the ligand identity and different crystal packing environments (Extended Data Fig. 3c -e), suggesting that it is likely to be a genuine feature of AT 2 R, rather than an artefact of crystallization. Helix VIII forms a highly complementary interface with the intracellular cavity of the 7TM bundle, and is stabilized by extensive hydrophobic interactions mediated by Phe325 , and helices III, V and VI (Fig. 2d ). Docking and molecular dynamics simulations suggest that helix VIII stabilizes the active-like conformation of the 7TM bundle of AT 2 R, while sterically blocking the binding of G proteins and β -arrestins (Fig. 2c) , which is consistent with the lack of robust downstream signalling by AT 2 R as assessed by traditional G protein and β -arrestin assays 4, 5 . In molecular dynamics simulations, helix VIII not only remained in the range of positions within r.m.s.d. values of less than 4 Å to the crystallographic structure for a total of 4 μ s of unbiased simulation (Extended Data Fig. 5a -c), but also quickly (< 200 ns) and reproducibly (n = 4) returned to this conformation after consequent perturbations of its position (Extended Data Fig. 5d , e). Alternatively, when helix VIII was relocated to the position observed in the AT 1 R structures, it relaxed into a canonical membrane-bound conformation, and this motion was accompanied by an inward shift of the intracellular tip of helix VI towards its position in the inactive state AT 1 R structure in three out of six independent molecular dynamics runs (Extended Data Fig. 5f -h).
Insights into ligand selectivity of AT 1 R and AT 2 R
Many AT 1 R and AT 2 R ligands share a biphenyl-tetrazole scaffold, important for ligand binding affinity. However, the molecular mechanisms of ligand selectivity between the two types of angiotensin receptor remain elusive. Our radioligand competition binding studies with compound 2 obtained inhibition constant (K i ) values of 3.7 nM and 0.35 nM for binding to AT 1 R and AT 2 R, respectively, indicating that this compound is a dual ligand with only about tenfold selectivity for AT 2 R over AT 1 R. By contrast, compound 1 exhibited an approximately 530-fold selectivity towards AT 2 R, with K i values of 180 nM and 0.34 nM for AT 1 R and AT 2 R, respectively (Extended Data Fig. 2c, e) .
In all three AT 2 R structures, strong electron density was observed in the orthosteric ligand-binding pocket, enabling accurate placement of both compounds 1 and 2 (Extended Data Fig. 6 ). We compared Article reSeArcH the positions and interactions of these compounds bound to AT 2 R with two ligands bound to AT 1 R (the AT 1 R-selective antagonist ZD7155, and the AT 1 R-selective inverse agonist olmesartan) (Fig. 3) . Surprisingly, despite the common scaffold, the ligands bind to the two receptor types very differently, with only the tetrazole moieties partially overlapping and forming crucial hydrogen bonds with an arginine in ECL2 (Arg167 ECL2 in AT 1 R and Arg182 ECL2 in AT 2 R). The overall biphenyl-tetrazole scaffold of the AT 2 R-bound ligands, however, is rotated about 45° as compared to its orientation in the AT 1 R-bound ligands, forming a distinct interaction pattern (Fig. 3a) . Notably, Arg , previously identified as key residues for ligand binding in AT 1 R, also provide crucial protein-ligand contacts in AT 2 R, although with different side-chain conformers. The side chain of Trp100 2.60 in AT 2 R is shifted about 3.1 Å compared to Trp84 2.60 in AT 1 R to form hydrophobic interactions with the thiophene ring of compound 1 and the benzene ring of compound 2, both on the carbonyl side of the AT 2 R ligands. On the other side of the carbonyl moiety, Thr88 2.64 in AT 1 R is replaced by Tyr104 2.64 in AT 2 R that forms new hydrophobic interactions with the benzene ring of compound 1 and the furan ring of compound 2. Moreover, the tetrazole moiety of the AT 2 R ligands is engaged in new polar interactions with the side chains of Lys215 (Fig. 3b, c) . In AT 1 R, Tyr292
7.43 forms a hydrogen bond with the backbone of helix III, while in AT 2 R, Phe308 7.43 is unable to form this interaction and is shifted over together with a pronounced shift in the backbone of helix VII. This rearrangement opens a sub-pocket for the binding of the ethyl and propyl moieties of compounds 1 and 2. Overall, these changes result in different shapes of the ligand-binding pocket between the two angiotensin receptors and a deeper ligand binding in AT 2 R. To gain additional insights into the selectivity of receptor types, we modelled an active-like state for AT 1 R and an inactive state for AT 2 R, and performed unrestrained cross-docking of ZD7155, olmesartan, and compounds 1 and 2 into the crystal structures and models of both receptors (Extended Data Fig. 7) . The results suggest that although the conformational state of AT 2 R has little effect on the ligand binding affinity, the predicted active-like conformation of AT 1 R is not compatible with binding of any of the tested ligands, corroborating the status of these ligands as antagonists for AT 1 R. Furthermore, the binding modes of these ligands are imposed by the distinct shapes of the binding pockets of the two receptors. Indeed, the biphenyl-tetrazole moieties of compounds 1 and 2 docked to the crystal structure of AT 1 R strongly preferred similar binding modes to those of olmesartan and ZD7155 (Extended Data Fig. 7a, b) . The only differences were observed in the orientation of the benzene and heterocyclic rings of compounds 1 and 2, which occupy the top of the ligand-binding pocket, beyond the interaction site of olmesartan and ZD7155. Similarly, docking into the AT 2 R structure suggested that ZD7155 and olmesartan can fit in the AT 2 R pocket, with their biphenyl-tetrazole scaffolds closely following the scaffolds of compounds 1 and 2 in the corresponding AT 2 R crystal structures. Although docking supports binding of all four ligands in both the AT 1 R and AT 2 R crystal structures, the binding scores of the ligands vary considerably, reflecting different interactions of nonscaffold groups. The scores also qualitatively reflect differences in the affinities of these compounds, with the cognate ligands showing substantially better binding scores than the off-target binders.
Ligand-binding pocket mutations validate structures
Point mutations were introduced in 17 residues of the AT 2 R ligandbinding pocket, and their effects on ligand affinity were assessed for [
3 H]angiotensin II peptide, as well as for the small-molecule compounds 1 and 2 in [ 3 H]angiotensin II competition assays (Supplementary Discussion and Extended Data Fig. 8) .
Overall, the effects of mutations in the binding pocket of AT 2 R are consistent with the receptor-ligand interactions observed in the co-crystal structures with compounds 1 and 2. Most of these effects are also distinct from the effects in AT 1 R-sartan complexes, corroborating the substantial differences in the ligand binding modes between AT 2 R and AT 1 R. Note that the effects of binding pocket mutations are practically identical for compounds 1 and 2, with the only notable exception of Trp269 6.48 Phe modestly (around fivefold) affecting the affinity of compound 1, but not of compound 2.
SAR provides insights into receptor selectivity
The structure-activity relationship (SAR) of compound 1 analogues was studied using derivatization of the 3-(R 1 ) and 7-(R 2 ) positions of the quinazolinone core (Extended Data Table 2), and its structural basis was analysed by molecular docking to the AT 1 R and AT 2 R crystal structures (Fig. 4) . The SAR dataset comprised a series of 14 compounds spanning a wide range of selectivity for the two receptor types. Two members of the series were found to be highly selective for AT 2 R (530-fold for compound 1 and 410-fold for compound 3), and two others showed a high degree of selectivity for AT 1 R (1,120-fold for compound 9 and 180-fold for compound 13). The remaining compounds exhibited moderate (< 15-fold) to no selectivity.
The SAR data showed that the R 1 substituent is crucial for high AT 2 R selectivity, whereas the R 2 substituent mostly defines a high selectivity towards AT 1 R (Extended Data 
Conclusions
The two types of the angiotensin II receptor are distinct in terms of their genetic variations, tissue-specific expression, signalling and regulation, as well as other physiological and pharmacological properties 1, 47 . Although all of the conserved motifs of class A GPCRs are present in AT 2 R, it exhibits an atypical behaviour compared to other receptors 1 . Discerning the AT 2 R-specific signalling pathways has been challenging and remains unresolved to date 4, 5 . The features revealed in the AT 2 R structures reported here might provide potential explanations for its poor coupling to G proteins and β -arrestins. On the basis of our results, we propose that helix VIII can play a dual role in the modulation of AT 2 R function. On the one hand, upon adopting a conformation captured in the crystal structures, helix VIII may stabilize an activelike receptor state, while repressing canonical AT 2 R activity in a selfinhibitory manner by sterically blocking the G protein and β -arrestin binding sites. On the other hand, upon switching to a membrane-bound conformation, helix VIII can support the recruitment of G proteins and β -arrestins for AT 2 R signalling. Therefore, helix VIII may work as a gatekeeper for either suppression or activation of the receptor depending on its post-translational modifications and interactions with various receptor partners and its environment. This hypothesis is consistent with the previously observed failure of AT 2 R to internalize, thus prolonging biological responses without desensitization 48, 49 . Further investigation is needed to understand this phenomenon fully.
Both angiotensin II receptors are important drug targets, since the blockade of AT 1 R has anti-hypertensive effects, while the modulation of AT 2 R could be useful for cardioprotection, neuropathic pain relief and the treatment of several other conditions. Designing molecules that selectively bind to a specific receptor type is often challenging, but can be crucial for different therapeutic purposes. Although the AT 1 R and AT 2 R ligands share common scaffolds, the ligand-binding pockets of these two receptors are markedly different, and these differences could be exploited for designing selective ligands. The AT 2 R crystal structures determined in this study improve our understanding of the two types of the human angiotensin receptor and provide new insights into the structural basis for the binding and selectivity of small molecules of therapeutic significance. Our results are therefore expected to facilitate the rational structure-based drug design for improved selectivity.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Protein engineering for structural studies. DNA encoding the human AT 2 R (UNIPROT P50052) was synthesized by GenScript with optimization for expression in insect cells. The construct has truncations of the AT 2 R residues 1-34 and 336-363. The thermostabilized apocytochrome b 562 RIL (BRIL) from Escherichia coli with mutations Met7Trp, His102Ile and Arg106Leu was fused to the N terminus of AT 2 R, with a four-residue linker (Gly-Ser-Gly-Ser). The BRIL-AT 2 R chimaera sequence was subcloned into vector pFastBac1 (Invitrogen), with N-terminal haemagglutinin (HA) signal sequence, a Flag tag, a 10 × His tag, and a tobacco etch virus (TEV) protease cleavage site. Protein expression and purification. The BRIL-AT 2 R protein was expressed in Spodoptera frugiperda (Sf9) insect cells (ATCC CRL-1711) using the Bac-to-Bac baculovirus expression system (Invitrogen). Cells were lysed by repeated washing and centrifugation, with hypotonic buffer (10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl) and high osmotic buffer (10 mM HEPES, pH 7.5, 1.0 M NaCl, 10 mM MgCl 2 , 20 mM KCl), adding EDTA-free complete protease inhibitor cocktail tablets (Roche). The washed membranes were suspended in hypotonic buffer with 2 mg ml −1 iodoacetamide for 30 min at 4 °C, and then solubilized in 100 mM HEPES, pH 7.5, 800 mM NaCl, 0.5% (w/v) n-dodecyl-β -d-maltopyranoside (DDM, Anatrace), 0.1% (w/v) cholesterol hemisuccinate (CHS, Sigma-Aldrich), and 10% (v/v) glycerol, for 4 h at 4 °C. The solubilized BRIL-AT 2 R protein was then bound to TALON IMAC resin (Clontech) overnight. The resin was washed with 10 column volumes of wash buffer I (50 mM HEPES, pH 7.5, 400 mM NaCl, 5% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10 mM imidazole), and 10 column volumes of wash buffer II (20 mM HEPES, pH 7.5, 200 mM NaCl, 5% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 20 mM imidazole). The BRIL-AT 2 R protein was eluted by three column volumes of elution buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 5% (v/v) glycerol, 0.02% (w/v) DDM, 0.004% (w/v) CHS, 300 mM imidazole), then incubated with 100 μ M of ligand (compound 1 or 2), treated overnight with TEV protease to remove tags, and concentrated to 15 mg ml −1 with a 100 kDa cutoff concentrator (Vivaspin). The protein yield and monodispersity were tested by analytical size exclusion chromatography. Lipidic cubic phase crystallization. The AT 2 R protein was reconstituted in LCP by mixing the protein with monoolein supplemented with 10% (w/w) cholesterol at a protein/lipid ratio of 2:3 (v/v) using a lipid syringe mixer. Crystallization trials were performed with an NT8-LCP robot (Formulatrix) in 96-well glass sandwich plates (Marienfeld) using 40 nl protein-loaded LCP and 800 nl precipitant solution per well. Plates were stored at 20 °C and imaged using a RockImager 1000 (Formulatrix). Crystals of AT 2 R-compound 2 grew to an average size of 70 × 40 × 20 μ m 3 within 21 days in 100 mM Tris-HCl, pH 8.0, 25-100 mM potassium formate, 25-35% (v/v) PEG400, and 0.3-1.2% (w/v) 1,6-hexanediol. Crystals were harvested using micromounts (MiTeGen) directly from LCP and flash-frozen in liquid nitrogen for diffraction data collection at the synchrotron radiation beamline. Micro-crystals of AT 2 R-compound 1 for XFEL data collection were prepared by injecting 5 μ l protein-laden LCP aliquots into 100 μ l gas-tight syringes filled with 60 μ l precipitant solution (100 mM Tris-HCl, pH 8.0, 25 mM potassium formate, 25% (v/v) PEG400, and 0.3% (v/v) (+ /− )-2-methyl-2,4-pentanediol). The crystals grew to an average size of 5 × 2 × 2 μ m 3 within 5 days at 20 °C. Before loading the micro-crystals into the LCP injector, the excess precipitant solution was carefully removed from the syringes, and the remaining LCP with embedded crystals was consolidated together. Approximately 20% (v/v) 7.9 MAG was added and mixed with the LCP, to absorb the residual precipitant solution and prevent the formation of lamellar crystalline phase due to rapid evaporative cooling when injecting LCP into vacuum 34 . Diffraction data collection using synchrotron radiation. Crystallographic diffraction data collection was performed at 23ID-D beamline (GM/CA) of the Advanced Photon Source in the Argonne National Laboratory. Diffraction data from 47 crystals of AT 2 R-compound 2 were collected using a Pilatus3 6M detector with an unattenuated 10 μ m minibeam (wavelength 1.0330 Å). Data were collected using 2 s exposure and 0.5° oscillation with the maximum wedge of 20° per crystal, and then integrated, scaled and merged using XDS 50 . Diffraction data collection using X-ray free-electron laser. SFX data collection was performed using the CXI instrument at the Linac Coherent Light Source (LCLS) at SLAC National Accelerator Laboratory. The LCLS was operated at a wavelength of 1.3 Å (9.57 keV) delivering individual X-ray pulses of 40 fs pulse duration and approximately 10 11 photons per pulse focused into a spot size of approximately 1.5 μ m in diameter using a pair of Kirkpatrick-Baez mirrors. Microcrystals of AT 2 R-compound 1 were delivered in the LCP media using a microextrusion injector 34 with 50 μ m nozzle running at a flow rate of approximately 220 nl min −1
. Diffraction images were recorded at a rate of 7,200 patterns per minute (120 Hz) with the 2.3 Megapixel Cornell-SLAC Pixel Array Detector (CSPAD). A total of 2,701,530 images were collected, 175,241 of which were identified as hits with the Cheetah program (6.5% hit rate). Surprisingly, indexing revealed two different lattices, monoclinic and orthorhombic, apparently belonging to different microcrystals of AT 2 R-compound 1 co-existing in the same crystallization batch. Therefore, 22,774 hits were successfully indexed in a 2/m Laue group and 15,804 hits in a mmm Laue group with different lattice parameters. Both datasets were merged separately using the standard CrystFEL (version 0.6.1+ f5db71cc) pipeline 51 of Monte Carlo averaging without additional scaling step applying per-pattern resolution cutoff with 'pushres 1.2' option. Structure determination. The structure was initially solved using molecular replacement with the monoclinic datasets collected at XFEL and synchrotron source. Molecular replacement models for AT 2 R were produced by alignment of AT 2 R sequence with sequences of previously solved GPCRs. The top 20 templates were further edited to preserve the conserved residues and trim non-conserved residues to alanines. Molecular replacement search with Phaser 52 identified locations of two receptors in asymmetric unit with a TFZ > 9. A further molecular replacement search with fixed positions of the two receptors using PDB code 1MT6 as the search model for BRIL found one BRIL molecule in the asymmetric unit. Refinements and model completion were performed by repetitive cycling between Refmac5 and autoBUSTER, followed by manual examination and rebuilding of the refined coordinates in Coot 53 , using both 2mF o − DF c and mF o − DF c maps, as well as omit maps calculated using Bhat's procedure 54 . The second BRIL molecule was modelled manually in the available electron density when the R free value dropped below 0.33. The final data collection and refinement statistics are shown in Extended Data Table 1 . The Ramachandran statistics determined by MolProbity 55 are as follows: 96.8% in the favoured region, 3.2% allowed, 0 outlier for monoclinic AT 2 R-compound 1; 97.6% in favoured region, 2.4% allowed, 0 outlier for orthorombic AT 2 R-compound 1; 97.4% in favoured region, 2.6% allowed, 0 outlier for AT 2 R-compound 2. Docking simulations. AT 1 R-and AT 2 R-selective and non-selective ligands were docked into the AT 1 R and AT 2 R crystal structures, AT 1 R active-like state and AT 2 R inactive state models using an energy-based docking protocol implemented in ICM molecular modelling software (Molsoft, LLC). The structures of the receptors were protonated and optimized using an ICM docking pipeline. The active and inactive state receptor models were obtained using homology modelling algorithm implemented in ICM. Crystal structures of AT 2 R and AT 1 R were used as templates for the AT 1 R active-like state model and the AT 2 R inactive state model, respectively. Molecular models of the compounds were generated from two-dimensional representations and their three-dimensional geometry was optimized using MMFF-94 force field 56 . Molecular docking used biased probability Monte Carlo (BPMC) optimization of the ligand internal coordinates in the grid potentials of the receptor ). The unbiased docking procedure did not use distance restraints or any other a priori derived information for the ligand-receptor interactions. Molecular dynamics. The initial receptor coordinates were derived from the AT 2 R crystal structures in complexes with compounds 1 and 2. The N-terminal fusion partner BRIL was removed and the terminal amino acids Cys35 and Arg337 were acetylated and amidated, respectively. We used ICM-Pro package (http://www. molsoft.com) to construct the model in the regions of missing electron densities for side chains and especially for the intracellular loop (ICL) regions. The orientations of AT 2 R in the apo and the ligand bound models were aligned to AT 1 R orientation in the membrane taken from the OPM database (http://www.opm.phar.umich.edu).
Initial ligand parameterization was performed in CGenFF available with CHARMM-GUI interface 58 . For corrections in charge assignments with high penalty values, compounds 1 and 2 were fragmented and re-parameterized using Gaussian03 package and Force Field Tool-Kit available with VMD v.1.9.2 (ref. 59 ). CHARMM36 additive force field was used for rest of the system 60 .We used homogenous lipid bilayer of 164 palmitoyloleoylphosphatidylcholine (POPC) lipids. TIP3P water model used for solvation of the lipids-receptor-ligand system with 150 mM salt concentration of Na + and Cl − . The initial input files generated using CHARMM-GUI interface were simulated using GROMACS v.5.0.4 molecular simulation package compiled to run in parallel computing architecture using multiple GPUs 61 . Each simulation was performed on a cluster of 4 nodes connected via InfiniBand, where a single node had 16 Intel Xeon 2.4 GHz processors and 2 NVIDIA Tesla K20 GPUs. Simulation parameters include a 1 fs time step for the initial phase of the equilibration, followed by a 2 fs time step for the rest of the equilibration and production simulations. During initial phase of NVT ensemble, temperature was set at 310 K using Berendsen for the centre of mass of C α atoms of residues Phe325-Lys328 compared to the crystal structure of AT 2 R. Tick marks on the y axis show the starting frame r.m.s.d. values. Coloured lines are plotted using values averaged over a 500 ps window. f-h, Results of molecular dynamics simulations for a modified AT 2 R model with the backbone of helix VIII aligned with helix VIII from AT 1 R structure (PDB code 4YAY). Conformational snapshots of the AT 2 R model (f) are shown for every 100 ns (blue to red spectrum) from one of the six independent 700 ns molecular dynamics simulation runs (simulation 5). Green cartoon shows inactive-state conformation of CCR5 (PDB code 4MBS), helix VIII of which was found to be the closest to the final conformations of AT 2 R helix VIII in molecular dynamics simulations. Intracellular view (g) of snapshots from the same molecular dynamics simulation is shown, but at t = 0 and t = 700 ns. Traces of the distance between helices VI and II (h, top curves), calculated between the centres of mass of C α atoms of residues Gln253 6.32 -Met257 6.36 in helix VI and residues Ser79 2.39 -Ile83 2.43 in helix II, show a change from 21 Å (active state) to under 16 Å (inactive state). Traces of the distance between helix VIII and the membrane (h, bottom curves), calculated between the centre of mass of C α atoms of residues Arg330-Val332 and the closest phosphate atoms of lipid molecules, indicate a gradual shift of helix VIII towards the lipid bilayer, with the distance decreasing from ~ 10 Å to under 3 Å.
